Gilead reveals data from Phase 4 TERISA study of angina drug

According to the study data, the addition of ranolazine to background antianginal therapy demonstrated reduced angina frequency in chronic angina patients with type 2 diabetes as compared to placebo and background antianginal therapy.

The TERISA study lead author and St. Luke’s Mid America Heart Institute cardiologist, the University of Missouri associate professor of medicine Mikhail Kosiborod said, "Although the safety and efficacy profile of ranolazine is well established, this is the first study to prospectively evaluate the antianginal effectiveness of ranolazine in patients with chronic angina and concurrent type 2 diabetes."

In the study, patients administered with ranolazine reported a lower average weekly angina frequency compared to placebo group patients.

A similar adverse event profile and discontinuations due to adverse events were observed between the ranolazine and placebo groups.

Non-serious adverse events noted in the study include nausea, dizziness and constipation.